More U.S. insurance providers are now expanding coverage to include TMS treatment for adolescents (ages 15+) with Major Depressive Disorder—creating a new path to care for younger patients who need additional options.

This means practices using FDA-cleared Magstim Horizon and Inspire TMS systems may be able to treat adolescent patients, pending prior authorization, under updated policies from major insurers including Optum, Aetna, Cigna, Humana, TRICARE, and others.

For adolescents and families seeking alternatives to antidepressant medications, this expanded coverage represents meaningful progress toward access, choice, and noninvasive care.

*Coverage varies by plan—providers should confirm benefits directly with individual insurance carriers.

Horizon 3.0 Transcranial Magnetic Stimulation Therapy Systems are indicated as an adjunct for the treatment of MDD in adolescent patients (age 15-21).